{
    "nct_id": "NCT02952508",
    "official_title": "An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)",
    "inclusion_criteria": "All Patients\n\n* Histologically or cytologically confirmed MM; Patients with primary or secondary CNSL may be enrolled.\n* ECOG performance status of 0 to 2\n* 18 years of age or older\n* Life expectancy of at least 6 months\n* Platelets ≥ 75,000/µL (if full-dose anticoagulation therapy is used, platelets ≥ 100,000/µL are required)\n* WBC count ≥ 3000/µL\n* Absolute neutrophil count ≥ 1500/µL\n* Hemoglobin ≥ 9 g/dL (last transfusion, if any, must be at least 1 week prior to study registration, and no transfusions are allowed between registration and dosing)\n* Estimated glomerular filtration rate ≥ 30 mL/min/1.73 m2\n* Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN)\n* Bilirubin < 1.5 × ULN\n* International normalized ratio (INR) < 2.5\n* If patient is on full-dose anticoagulation therapy, the anticoagulation therapy must be reversible and reversal of the anticoagulation therapy must not be life-threatening, as judged by the Investigator\n* Patients who have undergone stem cell transplant must be at least 100 days from transplant\n\nPatients with Multiple Myeloma\n\n* At least 5 prior regimens, which must include at least 1 approved proteasome inhibitor (bortezomib, carfilzomib, or ixazomib), at least 1 approved immunomodulatory agent (thalidomide, lenalidomide, or pomalidomide), and at least 1 approved monoclonal antibody (e.g., daratumumab or elotuzumab) with or without maintenance therapy, unless patients are intolerable to such agents or ineligible to receive such agents.\n* At least triple-class refractory (refractory to a proteasome inhibitor, immunomodulatory agent, and a monoclonal antibody)\n* Progressive disease defined by any of the following:\n\n  * 25% increase in serum M-protein from the lowest response value during (or after) last therapy and/or absolute increase in serum M-protein of ≥ 0.5 g/dL\n  * 25% increase in urine M-protein from the lowest response value during (or after) last therapy and/or absolute increase in urine M-protein of ≥ 200 mg/24 h\n  * 25% increase in bone marrow plasma cell percentage from the lowest response value during (or after) last therapy. Absolute bone marrow plasma cell percentage must be ≥ 10% unless prior CR when absolute bone marrow plasma cell percentage must be ≥ 5%.\n  * 25% increase in serum FLC level from the lowest response value during (or after) last therapy; the absolute increase must be > 10 mg/dL\n  * New onset hypercalcemia > 11.5 mg/dL\n  * Failure to obtain a partial response or better to current treatment, or cannot further improve their response to current treatment\n  * Appearance of new extramedullary disease\n* Measurable disease defined by any of the following:\n\n  * Serum M-protein > 0.5 g/dL\n  * Urine M-protein > 200 mg/24 h\n  * Serum FLC assay: Involved FLC level ≥ 10 mg/dL provided serum FLC ratio is abnormal.\n\n[CLOSED] Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma/Waldenstom Macroglobulinemia, or Marginal Zone Lymphoma\n\n* Prior treatment with at least 2 prior regimens, which may include chemotherapy, an approved anti-CD20 antibody with or without maintenance therapy, and an approved targeted agent, unless patients are ineligible to receive such agents\n* Patients with Helicobacter pylori+ mucosa-associated lymphoid tissue lymphoma must have received 1 prior antibiotic regimen for H pylori\n* At least 1 measurable nodal lesion with longest diameter > 15 mm or 1 measurable extranodal lesion (eg, hepatic nodule) with longest diameter > 10 mm. Additional parameters (e.g., measurable IgM for patients with Lymphoplasmacytic Lymphoma) may be allowed if they meet current NCCN guidelines for symptomatic disease. Patients with uptake by FDG-PET scan may be allowed with prior approval of Sponsor.\n\n[CLOSED] Patients with Mantle Cell Lymphoma\n\n* Prior treatment with at least 1 prior regimen\n* At least 1 measurable nodal lesion with longest diameter > 15 mm or 1 measurable extranodal lesion (eg, hepatic nodule) with longest diameter > 10 mm. Patients with uptake by FDG-PET scan may be allowed with prior approval of Sponsor.\n\n[CLOSED] Patients with Diffuse Large B-Cell Lymphoma\n\n* Relapsed or refractory to combination chemotherapy for DLBCL that contains rituximab and an anthracycline; or is intolerable to such agents. Relapsed disease is defined as either recurrence of disease after a CR or PD after achieving a partial response (PR) or SD. Refractory disease is defined as failure to achieve at least SD with any 1 line of therapy or with PD ≤ 3 months of the most recent chemotherapy regimen.\n* At least 1 measurable nodal lesion with longest diameter > 15 mm or 1 measurable extranodal lesion (eg, hepatic nodule) with longest diameter > 10 mm. Patients with uptake by FDG-PET scan may be allowed with prior approval of Sponsor.\n\nPatients with CNS Lymphoma\n\n* Must have biopsy-proven disease and must have received at least one prior intervention for their disease.\n* Must be at least two weeks from CNS biopsy before administration of iopofosine I 131.\n* Must have at least one lesion with enhancement on brain imaging.\n* Stable (or decreasing) dose of corticosteroids or anti-convulsant medication for at least 7 days prior to dosing\n\n[CLOVER-1]\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Ongoing Grade 2 or greater toxicities due to previous therapies. Stable, tolerable Grade 2 AEs (eg, neuropathy) may be allowed.\n* Prior external-beam RT resulting in greater than 20% of total bone marrow receiving greater than 20 Gy.\n* Prior total body or hemi-body irradiation. Patients who have received prior low-dose total body or hemi-body irradiation may be allowed on a case-by-case basis after discussion with Sponsor (considerations may include factors such as time since irradiation, total lifetime accumulated dose, etc.)\n* Extradural tumor in contact with the spinal cord or tumor located where swelling in response to therapy may impinge upon the spinal cord\n* For patients with CLL/SLL, LPL, or MZL, transformation to a more aggressive form of NHL\n* Ongoing chronic immunosuppressive therapy\n* Clinically significant bleeding event within prior 6 months\n* Ongoing anti-platelet therapy (except low-dose aspirin [eg, 81 mg daily] for cardioprotection)\n* Anti-cancer therapy within two weeks of initial iopofosine I 131 infusion. Low dose dexamethasone for symptom management is allowed\n* Radiation therapy, chemotherapy, immunotherapy, or investigational therapy within 2 weeks of eligibility-defining bone marrow biopsy.\n* For patients with primary or secondary CNSL, active bleeding in the tumor bed and/or uncontrolled seizure activity\n\n[CLOVER-WaM] Inclusion Criteria\n\n* Histologically or cytologically confirmed WM. Patients with a diagnosis of LPL may be enrolled with prior Sponsor approval.\n* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 (Appendix C)\n* Patient is 18 years of age or older\n* Life expectancy of at least 6 months\n* Received at least two prior lines of therapy for WM\n* Measurable IgM (above upper limit of normal) OR at least one measurable nodal lesion with longest diameter > 15 mm or one measurable extranodal lesion (e.g., hepatic nodule) with longest diameter > 10 mm\n\n[CLOVER-WaM] Exclusion Criteria\n\n* Ongoing Grade 2 or greater toxicities due to previous therapies, excluding alopecia.\n* Prior external-beam RT resulting in greater than 20% of total bone marrow receiving greater than 20 Gy.\n* Prior total body or hemi-body irradiation. Patients who have received prior low-dose total body or hemi-body irradiation may be allowed on a case-by-case basis after discussion with Sponsor (considerations may include factors such as time since irradiation, total lifetime accumulated dose, etc.)\n* Patients with second malignancies in addition to WM, if the second malignancy has required therapy in the last 2 years or is not in remission; exceptions to this criterion include successfully treated non-metastatic basal cell or squamous cell skin carcinoma, or prostate cancer that does not require therapy\n* Anti-cancer therapy within two weeks of initial iopofosine I 131 infusion.\n* Need for acute treatment of WM (e.g., those with hyperviscosity)",
    "miscellaneous_criteria": "[CLOVER-1]"
}